Der Humanized Monoklonal anti-CD38 (Isatuximab Biosimilar) Antikörper (ABIN7795129) detektiert spezifisch CD38 (Isatuximab Biosimilar) in FACS und in vivo.
Dieser Antikörper reagiert spezifisch mit Proben aus Human.
Kurzübersicht für Rekombinanter CD38 (Isatuximab Biosimilar) Antikörper (ABIN7795129)
Target
CD38 (Isatuximab Biosimilar)
Antikörpertyp
Recombinant Antibody
Reaktivität
Human
Wirt
Humanized
Klonalität
Monoklonal
Konjugat
Dieser CD38 (Isatuximab Biosimilar) Antikörper ist unkonjugiert
Applikation
Flow Cytometry (FACS), In vivo Studies (in vivo)
Güteklasse
Research Grade
Expressionssystem
Mammalian cells
Verwendungszweck
Isatuximab Biosimilar, CD38 Monoclonal Antibody
Produktmerkmale
Isatuximab Biosimilar uses the same protein sequences as the therapeutic antibody isatuximab. Isatuximab is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line. Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains. It is a cytolytic antibody targeted against CD38, a glycoprotein found on the surface of some immune cells that is highly expressed by malignant plasma cells in multiple myeloma. Along with daratumumab, another anti-CD38 monoclonal antibody, isatuximab constitutes a novel treatment modality for patients with difficult-to-treat multiple myeloma.